知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

1379 条记录 (耗时 0.038 秒)

    RhoC-based immunotherapy
    64.
    发明授权
    RhoC-based immunotherapy 有权
    基于RhoC的免疫治疗

    公开(公告)号：US09163077B2

    公开(公告)日：2015-10-20

    申请号：US12808649

    申请日：2008-12-18

    申请人： Mads Hald Andersen ,  Per Thor Straten

    发明人： Mads Hald Andersen ,  Per Thor Straten

    IPC分类号： A61K39/00 ,  A61K35/12 ,  A61P35/00 ,  A61P35/04 ,  C07K14/82 ,  C07K14/47 ,  A61K38/00

    CPC分类号： A61K39/0011 ,  A61K38/00 ,  C07K14/4702 ,  C07K14/82 ,  C12N9/14 ,  C12Y306/05

    摘要： The present invention relates generally to the field of prophylaxis and therapy of metastatic cancer. In particular there is provided a protein; Ras Homology gene family, member C (RhoC) or peptide fragments thereof that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to use of RhoC or peptides derived thereof or RhoC specific T-cells for treatment of metastatic cancer. Hence, the invention in one aspect relates to RhoC specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. Also the use of RhoC and immunogenic peptide fragments hereof in cancer treatment, diagnosis and prognosis is provided.

    摘要翻译： 本发明一般涉及转移性癌症的预防和治疗领域。 特别是提供蛋白质; Ras同源基因家族，成员C（RhoC）或其能够引发抗癌免疫应答的肽片段。 具体地，本发明涉及RhoC或其衍生的肽或RhoC特异性T细胞用于治疗转移性癌症的用途。 因此，本发明在一个方面涉及通过疫苗接种转移或诱导的RhoC特异性T细胞作为癌症的治疗。 还提供了在癌症治疗，诊断和预后中使用RhoC和免疫原性肽片段。

    Phenotypic reversion of pancreatic carcinoma cells
    65.
    发明授权
    Phenotypic reversion of pancreatic carcinoma cells 有权
    胰腺癌细胞的表型逆转

    公开(公告)号：US09115213B2

    公开(公告)日：2015-08-25

    申请号：US13677876

    申请日：2012-11-15

    申请人： Matthew Pincus ,  Josef Michl

    发明人： Matthew Pincus ,  Josef Michl

    IPC分类号： A61K38/00 ,  C07K14/82

    CPC分类号： A61K38/46 ,  A61K38/00 ,  A61K48/00 ,  C07K14/82 ,  C07K2319/10 ,  C12N15/86 ,  C12N2710/10032 ,  C12N2710/10043 ,  C12Y306/05002

    摘要： The present invention provides peptides (including analogs and derivatives thereof) corresponding to residues 96-110 and 35-47 of ras-p21, which peptides have attached thereto a membrane-penetrating leader sequence. The subject peptides, analogs and derivatives thereof are useful in treatment of cancers and have been shown to induce phenotypic reversion of pancreatic cancer cells to non-cancerous cells. Pharmaceutical compositions comprising one or more subject peptides are also provided by the present invention. The present invention further provides replication incompetent Adenovirus (AdV) vectors comprising a promoter sequence and a nucleotide sequence encoding a subject peptide. Methods of treating cancer by administering one or more subject peptides, pharmaceutical compositions, and/or AdV vectors are also provided.

    摘要翻译： 本发明提供了对应于ras-p21的残基96-110和35-47的肽（包括其类似物和衍生物），该肽与其附着有膜穿透前导序列。 本发明的肽，类似物和衍生物可用于治疗癌症，并且已被证明能诱导胰腺癌细胞向非癌细胞的表型逆转。 包含一种或多种受试肽的药物组合物也由本发明提供。 本发明还提供了包含启动子序列和编码目标肽的核苷酸序列的复制无能力腺病毒（AdV）载体。 还提供了通过施用一种或多种受试肽，药物组合物和/或AdV载体治疗癌症的方法。

    HER-2 peptides and vaccines
    67.
    发明授权
    HER-2 peptides and vaccines 有权
    HER-2肽和疫苗

    公开(公告)号：US08895017B2

    公开(公告)日：2014-11-25

    申请号：US13701814

    申请日：2011-05-23

    申请人： Helen Kim Cho ,  Siradanahalli Chandrasekharalah Guru ,  Van To Tsai ,  Brian Gregory Pierce

    发明人： Helen Kim Cho ,  Siradanahalli Chandrasekharalah Guru ,  Van To Tsai ,  Brian Gregory Pierce

    IPC分类号： A61K39/00 ,  C07K14/71 ,  C07K14/82

    CPC分类号： C07K14/71 ,  A61K39/0011 ,  A61K2039/53 ,  C07K14/82

    摘要： The present invention provides (a) isolated immunogenic HER-2 peptides capable of inducing immune responses against human HER-2 receptor; (b) isolated nucleic acid molecules encoding an isolated immunogenic HER-2 peptide; (c) plasmid constructs comprising a nucleic acid molecule encoding an isolated immunogenic HER-2 peptide; (d) vaccine compositions comprising an isolated immunogenic HER-2 peptide (e) vaccine compositions comprising an isolated nucleic acid molecule encoding an isolated immunogenic HER-2 peptide; and (f) methods of treating or preventing cancer, inhibiting abnormal cell proliferation, or eliciting an immune response against HER-2 protein in a mammal using (1) an isolated immunogenic HER-2 peptide, (2) nucleic acid molecule encoding an isolated immunogenic HER-2 peptide, or (3) a composition comprising an isolated immunogenic HER-2 peptide, or composition comprising a nucleic acid molecule encoding an isolated immunogenic HER-2 peptide.

    摘要翻译： 本发明提供（a）能够诱导针对人HER-2受体的免疫应答的分离的免疫原性HER-2肽; （b）编码分离的免疫原性HER-2肽的分离的核酸分子; （c）包含编码分离的免疫原性HER-2肽的核酸分子的质粒构建体; （d）包含分离的免疫原性HER-2肽（e）疫苗组合物的疫苗组合物，其包含编码分离的免疫原性HER-2肽的分离的核酸分子; 和（f）使用（1）分离的免疫原性HER-2肽，（2）编码分离的免疫原性HER-2肽的核酸分子来治疗或预防癌症，抑制异常细胞增殖或引起哺乳动物中HER-2蛋白的免疫应答的方法 免疫原性HER-2肽，或（3）包含分离的免疫原性HER-2肽或包含编码分离的免疫原性HER-2肽的核酸分子的组合物的组合物。

    SUPPRESSION OF CANCERS
    68.
    发明申请
    SUPPRESSION OF CANCERS 审中-公开
    抑制癌症

    公开(公告)号：US20140219983A1

    公开(公告)日：2014-08-07

    申请号：US14250954

    申请日：2014-04-11

    申请人： Syntaxin Limited

    发明人： Frederic MADEC ,  Phil LECANE ,  Philip MARKS ,  Keith FOSTER

    IPC分类号： C12N9/50 ,  C07K14/60 ,  C07K14/33 ,  C07K14/82 ,  C07K7/08 ,  C07K14/48 ,  C07K14/575 ,  C07K14/65

    摘要： The present invention relates to a method for suppressing or treating cancer, in particular to a method for suppressing or treating one or more of colorectal cancer, breast cancer, prostate cancer and/or lung cancer. The therapy employs use of a non-cytotoxic protease, which is targeted to a growth hormone-secreting cell such as to a pituitary cell. When so delivered, the protease is internalised and inhibits secretion/transmission of growth hormone from said cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.

    摘要翻译： 本发明涉及抑制或治疗癌症的方法，特别涉及抑制或治疗结肠直肠癌，乳腺癌，前列腺癌和/或肺癌中的一种或多种的方法。 该疗法使用非细胞毒性蛋白酶，其靶向生长激素分泌细胞，例如垂体细胞。 当这样传递时，蛋白酶被内化并且抑制生长激素从所述细胞的分泌/传递。 本发明还涉及用于所述方法的多肽和核酸。